The BRAF V600E mutation is closely linked to tumorigenesis and malignant phenotype of
papillary thyroid cancer. Signaling pathways activated by BRAFV600E are still unclear …

The BRAFT1799A mutation is the most common genetic alteration in papillary thyroid
carcinomas (PTC). It is also found in a subset of papillary microcarcinomas, consistent with a …

Abstract BRAF V600E is a constitutively active onco-kinase and is the most common genetic
alteration in papillary thyroid carcinoma (PTC), and in anaplastic thyroid carcinoma as well …

Abstract Context: Although the BRAF V600E mutant can initiate the formation of papillary
thyroid cancer (PTC), it is unclear whether it is required to maintain cell proliferation …

Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC). To
model PTC, we bred mice with adult-onset, thyrocyte-specific expression of BRAFV600E …

Somatic mutations in BRAF, especially BRAFV600E, are frequently identified in papillary
thyroid cancer (PTC) tumors. It has been established that expression levels of numbers of …

BRAF, a cytoplasmic serine–threonine protein kinase, plays a critical role in cell signaling as
an activator within the mitogen-activated protein kinase (MAPK) pathway. The most common …

1. ABSTRACT BRAF is a cytoplasmic serine-threonine protein kinasethat plays a critical role
in the MAPK signaling pathway. BRAF is the only member of the RAF family activated by …

The activating mutation BRAF T1796A is the most prevalent genetic alteration in papillary
thyroid carcinomas (PTC). It is associated with advanced PTCs, suggesting that this …

Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …